Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CET

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN
01/19 AMGEN : "Drug Delivery Device with Live Button Or User Interface Field" in Paten..
01/19 AMGEN : EC approves Amgen's biosimilar Avastin
01/19 AMGEN : European Medicines Agency Accepts Filing For EVENITY Romosozumab
01/19 AMGEN : FDA Approves Addition Of Overall Survival Data To KYPROLIS (carfilzomib)..
01/19 AMGEN : Patent Application Titled "Feed Media" Published Online (USPTO 201703698..
01/17 AMGEN : FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib..
01/17 AMGEN : Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Tr..
01/15 AMGEN : Astellas Pharma Inc - Repatha SC Injection 420 mg Auto Mini Doser Launch..
01/11 AMGEN : FDA Approves XGEVA® denosumab For The Prevention Of Skeletal-Related Eve..
01/11 AMGEN : "Drug Delivery Device with Live Button Or User Interface Field" in Paten..
More news
News from SeekingAlpha
01/20 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 19, 2018
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 The Passive/Aggressive Portfolio
01/19 YOUR DAILY PHARMA SCOOP : Adamas' Gocovri, Onconova To Advance INSPIRE Study, Ag..
01/19 The MnM Portfolio, Dec. 2017 - Closing Out A Solid Dividend-Growth Year
Financials ($)
Sales 2017 22 889 M
EBIT 2017 11 760 M
Net income 2017 7 618 M
Finance 2017 6 853 M
Yield 2017 2,38%
P/E ratio 2017 18,34
P/E ratio 2018 17,95
EV / Sales 2017 5,70x
EV / Sales 2018 5,53x
Capitalization 137 B
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 193 $
Spread / Average Target 1,7%
EPS Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN8.84%137 400
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132